Clinical Trials Logo
  1. Home
  2. Pseudomonas Aeruginosa
  3. NCT01745796

Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN) — PYO GEN  

Pseudomonas Aeruginosa Clinical Trial

Official title:
Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia

Clinical Trial Summary

Pseudomonas aeruginosa is the main pathogen of nosocomial respiratory infections. Its increasing resistance to antibiotics requires the development of new strategies for prevention and control, demanding a better understanding of the modes of transmission and evolutionary dynamics of this bacteria. In patients under invasive mechanical ventilation, the main mode of contamination by Pseudomonas remains debated, with 3 modes of contamination (endogenous, crossed transmission between patients, or environmental origin) of varying importance, mainly depending on the endemic situation of the place of study. The emergence of new genotyping technologies (DiversiLab) can now facilitate studies of molecular epidemiology. Thanks to the multidisciplinary collaboration and innovative techniques, the investigators wish to study the impact of the mode of contamination on the outcome of ICU patients, intubated and ventilated for more than 72 hours.

Clinical Trial Description

The presence of environmental reservoirs can cause infections and multidrug-resistant P. aeruginosa colonization with P. aeruginosa is itself a prognostic factor, but the impact of the route of infection on the evolution of the history and future of the infectious patient is not established. A second factor that may influence the evolution infectious is the degree of genetic heterogeneity of the bacterial population. Multiple exposure pathways could also influence the genetic diversity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01745796
Study type Observational
Source University Hospital, Grenoble
Contact
Status Completed
Phase
Start date July 3, 2013
Completion date June 2, 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04335383 - Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Not yet recruiting NCT06035055 - Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis Phase 4
Completed NCT00774072 - Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization Phase 2
Completed NCT00515229 - Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo Phase 2
Terminated NCT00333385 - Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Phase 4
Recruiting NCT03638830 - Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa Phase 2
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT00633191 - Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis Phase 1/Phase 2
Completed NCT00712166 - Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa Phase 3
Recruiting NCT04171817 - Animal-Assisted Visitation Program Chlorhexidine Trial Phase 4
Completed NCT02696902 - Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects Phase 2
Completed NCT01319253 - A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies N/A
Recruiting NCT05282082 - Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Recruiting NCT04803695 - Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT05632315 - PMT for MDRO Decolonization Phase 2
Completed NCT01055847 - Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection Phase 2
Recruiting NCT04673175 - Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Recruiting NCT05616221 - Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection Phase 2
Terminated NCT03262142 - Targeted AntiBiotics for Chronic Pulmonary Diseases Phase 4